LOGIN
ID
PW
MemberShip
2025-07-04 10:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Product
Medical institutions earned ₩7 trillion with COVID-19
by
Kang, Shin-Kook
Jul 27, 2022 05:50am
A whole &8361;7.1028 trillion was spent on medical fees for COVID-19-related matters over the past two and a half years since the pandemic first hit Korea. The medical staff, acclaimed for their efforts in the pandemic, have also earned much for their incredible amount of hard work. In the same period, pharmacies have only earned around &83
Product
MOHW meets Doctornow to listen to platform guidelines
by
Kim JiEun
Jul 27, 2022 05:49am
The timing of the announcement of the guidelines for the non-face-to-face treatment brokerage platform announced by the government is later than expected. In addition to the opinions of the medical and pharmaceutical sectors, the government's intention to reflect some of the opinions of platform companies is read. It has been confirmed that t
Product
Sell Saxenda directly after non-face-to-face treatment?
by
Jung, Heung-Jun
Jul 10, 2022 03:31pm
Can hospitals sell Saxenda, known as diet injections, directly to patients after non-face-to-face treatment? It is an expensive drug worth more than 100,000 won per unit and there is a high demand for purchase, so it is not prescribed for outpatients. The problem is that some hospitals sell and deliver directly to patients even in non-face-to
Product
¡°Need to raise awareness and seek early diagnosis of Sjogre
by
Eo, Yun-Ho
Jul 1, 2022 05:49am
¡°We can fully provide the standard of care at local rheumatoid clinics. Have trust and visit a local clinic near you.¡± If you are experiencing symptoms such as dry mouth, eyes, nose and mucous membrane, skin, or indigestion without underlying diseases or other medication histories for over 3 months but haven¡¯t found its cause, it can b
Product
Approval of OTC teleconference bending machine project
by
Kang, Shin-Kook
Jun 23, 2022 05:49am
OTC teleconference bending machine issue, which has been on hold for 10 years, has secured a bridgehead for entering the market under the new government deregulation stance. The Ministry of Science and ICT held an ICT regulatory sandbox review committee on the 20th and approved the OTC teleconference bending machine based on the MOHW's co
Product
Prescription of oral COVID-19 drugs drop to 1,800 last week
by
Kang, Shin-Kook
Jun 13, 2022 05:54am
Prescriptions of the oral COVID-19 treatments Paxlovid and Lagevrio have been rapidly decreasing in line with the decrease of confirmed COVID-19 cases in Korea. On the 10th, the Korea Disease Control and Prevention Agency announced that it had prescribed Paxlovid and Lagevrio to 1,800 patients during the past week. From 6:30 p.m. on
Product
The supply of Tylenol suspension has been postponed again
by
Kim JiEun
May 25, 2022 05:47am
The sale of children's Tylenol suspension will be extended further. The supplier originally promised to supply it in June, but it seems that it will not be available until August, two months later. Johnson & Johnson Korea recently sent an official letter to drug distributors on the "Delay Notice on the Supply Schedule of Children's Tylenol Suspe
Product
Unsure efficacy of Alzheimer's drug aducanumab
by
Choi-sun
May 10, 2022 06:07am
The Korean Dementia Association has reviewed the clinical potential of aducanumab (Aduhelm), the first new drug for Alzheimer's disease to be introduced to the field in 18 years. With the efficacy of the drug under constant debate, and being barely approved for its effect in reducing surrogate biomarkers such as amyloid reduction in Korea and
Product
Aftermath of Revlimid of primary benefit multiple myeloma
by
Whang, byung-woo
Apr 28, 2022 06:06am
As Revlimid (Lenalidomide Hemihydrate) based chemotherapy enters the benefit, changes in RRMM prescription patterns are inevitable. Kyprolis-centered KRd therapy (Carfilzomib+Revlimid+Dexamethasone) and Ninlaro-centered IRd therapy ( As both Ixazomib+Revlimid+Dexamethasone) contain Revlimid, there are concerns at the clinical site about how
Product
The KPA establishes an emergency TFT
by
Apr 20, 2022 06:05am
As the presidential transition committee is expected to include the permission of non-face-to-face medical treatment in its national agenda and fully review the revision of the law, the KPA has begun to come up with measures. The Chairman Choi Kwang-hoon formed a TFT related to non-face-to-face treatment and convened his first meeting toda
1
2
3
4
5
6
7
8
9
10
>